Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PathoQuest Raises EUR 3.8 Million in Series B Financing Round

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
The new round of financing will be used for the first clinical study of a disruptive Next Generation Sequencing cloud-based diagnostic assay for infectious diseases.

PathoQuest has announced the closing of a new fundraising of EUR 3.8 million. This round brings in two new investors, Idinvest and Aurinvest, in addition to the existing investor Kurma Life Science Partners.

PathoQuest develops solutions for high unmet needs in clinical diagnosis of infectious diseases. The company, founded in 2010, previously raised EUR 2 million in March 2011.

The additional funds will allow PathoQuest to launch the first clinical study of a novel NGS-SaaS (Software as a Service) cloud based diagnostic assay. This assay is a bioinformatics workflow that is designed to assist the diagnostic decision-making.

This clinical study will target diagnosis of severe multi-etiological-based infectious episodes in immuno-compromised patients.

This immuno-suppression can be congenital or acquired, whether through immuno-suppressing treatment post-transplant or through anticancer chemotherapy.

For immuno-compromised patients, the current leading diagnostic approaches remain unsatisfactory. Current approaches are biased, because, as the targets are defined, in principle users can only find what they are looking for.

With NGS, users can identify any target, without prior selection. PathoQuest’s assay will allow identification of pathogens in two days, compared with several weeks with current approaches.

As a result, the diagnostic is more accurate and the cost is reduced. PathoQuest intends to launch a first commercial product in 2015, following an extension of this clinical trial in the US in the coming months.

“We are delighted to launch the first clinical trial with an unbiased diagnostic approach in the field of infectious diseases,” said Prof. Marc Eloit, president and CSO and Luc Boblet, CEO of PathoQuest.

Using a unique combination of proprietary sample prep and bio-IT algorithms, PathoQuest’s business model is based on ‘Software as a Service’ (SaaS).

In the area of infectious diseases, PathoQuest is the only company on the market to combine NGS of the whole genome of a pathogen with SaaS, while offering cloud computing access.

PathoQuest will act as an alternative to well established solutions on the market by offering reagent kits and distributed bio-IT services through this cloud computing model.

“We think the results of the first PathoQuest clinical trial will position the company to meet high medical needs with a good value solution,” said Thierry Laugel, managing partner at Kurma Life Sciences. “Helping to create highly innovative companies from an academic background continues to build the knowledge and experience of Kurma.”

“We are pleased to invest in such a promising project and to work in close connection with both the Pasteur Institute and KLS partners,” said Michel Demont, president of Aurinvest. “PathoQuest, is our sixth investment in the life sciences sector and our second with the Pasteur Institute.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!